These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31898040)

  • 41. Duodenal-jejunal bypass liner to treat type 2 diabetes mellitus in morbidly obese patients.
    Muñoz R; Escalona A
    Curr Cardiol Rep; 2014 Mar; 16(3):454. PubMed ID: 24570355
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of the endoscopic duodenal-jejunal bypass liner prototype in severe or morbidly obese subjects implanted for up to 3 years.
    Quezada N; Muñoz R; Morelli C; Turiel D; Hernández J; Pimentel F; Escalona A
    Surg Endosc; 2018 Jan; 32(1):260-267. PubMed ID: 28664427
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endoscopic Bariatric Treatment with Duodenal-Jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis.
    Karlas T; Petroff D; Feisthammel J; Beer S; Blüher M; Schütz T; Lichtinghagen R; Hoffmeister A; Wiegand J
    Obes Surg; 2022 Aug; 32(8):2495-2503. PubMed ID: 35713854
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Preclinical Animal Study of Combined Intragastric Balloon and Duodenal-Jejunal Bypass Liner for Obesity and Metabolic Disease.
    Ghoz H; Jaruvongvanich V; Matar R; Beran A; Maselli DB; Storm AC; Abu Dayyeh BK
    Clin Transl Gastroenterol; 2020 Sep; 11(9):e00234. PubMed ID: 33094961
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide.
    Ryder REJ; Laubner K; Benes M; Haluzik M; Munro L; Frydenberg H; Teare JP; Ruban A; Fishman S; Santo E; Stengel R; De Jonge C; Greve JW; Cohen RV; Aboud CM; Holtmann GJ; Rich G; McMaster JJ; Battelino T; Kotnik P; Byrne JP; Mason JC; Bessell J; Bascomb J; Kow L; Collins J; Chisholm J; Pferschy PN; Sourij H; Cull ML; Wyres MC; Drummond R; McGowan B; Amiel SA; Yadagiri M; Sen Gupta P; Aberle J; Seufert J
    Diabetes Care; 2023 Apr; 46(4):e89-e91. PubMed ID: 36716004
    [No Abstract]   [Full Text] [Related]  

  • 46. Duodenal-jejunal bypass liners: outcomes in glycaemic control and weight loss.
    Neff KJ; Miras AD; le Roux C
    Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):420-8. PubMed ID: 23974770
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes.
    Cohen RV; Neto MG; Correa JL; Sakai P; Martins B; Schiavon CA; Petry T; Salles JE; Mamedio C; Sorli C
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E279-82. PubMed ID: 23337729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initial human experience with restrictive duodenal-jejunal bypass liner for treatment of morbid obesity.
    Escalona A; Yáñez R; Pimentel F; Galvao M; Ramos AC; Turiel D; Boza C; Awruch D; Gersin K; Ibáñez L
    Surg Obes Relat Dis; 2010 Mar; 6(2):126-31. PubMed ID: 20359665
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Duodenal-jejunal lining increases postprandial unconjugated bile acid responses and disrupts the bile acid-FXR-FGF19 axis in humans.
    van Nierop FS; de Jonge C; Kulik W; Bouvy N; Schaap FG; Olde Damink SW; Rensen S; Romijn JA; Greve JWM; Soeters MR
    Metabolism; 2019 Apr; 93():25-32. PubMed ID: 30658059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Change of cardiovascular risk associated serologic biomarkers after gastric bypass: A comparison of diabetic and non-diabetic Asian patients.
    Wei JH; Lee MH; Lee WJ; Chen SC; Almalki OM; Chen JC; Wu CC; Lee YC
    Asian J Surg; 2022 Nov; 45(11):2253-2258. PubMed ID: 35012855
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Duodenal-jejunal bypass liner implantation provokes rapid weight loss and improved glycemic control, accompanied by elevated fasting ghrelin levels.
    Koehestanie P; Dogan K; Berends F; Janssen I; Wahab P; Groenen M; Müller M; de Wit N
    Endosc Int Open; 2014 Mar; 2(1):E21-7. PubMed ID: 26134609
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The feasibility of delivering a duodenal-jejunal bypass liner (EndoBarrier) endoscopically with patients under conscious sedation.
    Koehestanie P; Betzel B; Dogan K; Berends F; Janssen I; Aarts E; Groenen M; Wahab P
    Surg Endosc; 2014 Jan; 28(1):325-30. PubMed ID: 23982649
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease.
    de Jonge C; Rensen SS; Koek GH; Joosten MF; Buurman WA; Bouvy ND; Greve JW
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1517-20. PubMed ID: 23920034
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [EndoBarrier as a treatment for obesity and diabetes].
    Greve JWM; Bouvy ND
    Ned Tijdschr Geneeskd; 2018; 162():D2268. PubMed ID: 29519261
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Weight-Loss Endoscopy Trial: A Multicenter, Randomized, Controlled Trial Comparing Weight Loss in Endoscopically Implanted Duodenal-Jejunal Bypass Liners versus Intragastric Balloons versus a Sham Procedure.
    Hollenbach M; Feisthammel J; Prettin C; Gundling F; Schepp W; Stein J; Petroff D; Hoffmeister A
    Digestion; 2024; 105(6):468-479. PubMed ID: 38885635
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Innovative metabolic operations.
    Cohen R; Caravatto PP; Petry TZ
    Surg Obes Relat Dis; 2016 Jul; 12(6):1247-55. PubMed ID: 27317607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endoscopic Therapeutic Option for Weight Loss and Control of Type 2 Diabetes: the Duodenal-Jejunal Bypass Liner.
    de Moura EG; Orso IR; Martins BC; Lopes GS
    Surg Technol Int; 2015 May; 26():115-9. PubMed ID: 26054998
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Duodenal-jejunal bypass liner for the treatment of type 2 diabetes and obesity: 3-year outcomes in the First National Health Service (NHS) EndoBarrier Service.
    Ryder REJ; Yadagiri M; Burbridge W; Irwin SP; Gandhi H; Bashir T; Allden RA; Wyres M; Cull M; Bleasdale JP; Fogden EN; Anderson MR; Sen Gupta P
    Diabet Med; 2022 Jul; 39(7):e14827. PubMed ID: 35285080
    [No Abstract]   [Full Text] [Related]  

  • 59. New Anchoring Mechanism and Design of an Endoluminal Duodeno-Jejunal Bypass Liner for Treatment of Obesity: a Pilot Animal Trial.
    Frydenberg Am HB; Suturin VM; Truong H; Ryan A; Soutorine M
    Obes Surg; 2019 Sep; 29(9):3081-3085. PubMed ID: 31127497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trends in BMI, Glycaemic Control and Obesity-Associated Comorbidities After Explantation of the Duodenal-Jejunal Bypass Liner (DJBL).
    Kassir R; Gugenheim J; Amor IB; Kassir R; Sauvat F
    Obes Surg; 2018 Nov; 28(11):3629-3630. PubMed ID: 30145630
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.